Commonwealth Equity Services
AGRX

Commonwealth Equity Services’s Agile Therapeutics AGRX Stock Holding History

Commonwealth Equity Services’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6
Closed -$15K – 2963
2019
Q3 		$15K Buy
+6
New +$14.8K ﹤0.01% 2808

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Commonwealth Equity Services's AGRX Position: Q4 2019 in Review

Commonwealth Equity Services sold out of Agile Therapeutics (AGRX) in Q4 2019, closing a stake of 6 shares — an estimated $15K sold.

Commonwealth Equity Services first reported a position in AGRX in Q3 2019 and held it in 1 quarter. The position peaked at $15K in Q3 2019. 46 funds tracked by Wall St. Rank hold AGRX as of Q4 2019.

  • Commonwealth Equity Services reported no remaining Agile Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Commonwealth Equity Services sold 6 Agile Therapeutics shares in Q4 2019, an estimated $15K.
  • Commonwealth Equity Services first reported a position in Agile Therapeutics in Q3 2019 and held it in 1 quarter.
  • Commonwealth Equity Services's Agile Therapeutics position peaked at $15K in Q3 2019.
  • 46 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2019.

Based on Commonwealth Equity Services's 13F filing for Q4 2019, filed 5 Feb 2020.